Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
19 août 2021 22h20 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten...
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
19 août 2021 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market...
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
12 août 2021 16h01 HE
|
Progenity, Inc.
Announced successful completion of the validation study PRO-104 for the Preecludia™ rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved...
Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
05 août 2021 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on...
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
29 juil. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
30 juin 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July...
Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
17 juin 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory...
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
15 juin 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder...
NASDAQ: PROG Investor Notice: Update in Lawsuit against Progenity, Inc. announced by Shareholders Foundation
15 juin 2021 07h10 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that an update in the lawsuit that is pending for certain investors in NASDAQ: PROG shares. Investors, who...
Progenity Announces $40 Million Private Placement
10 juin 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities...